Phase III MEASURE 2 study data on Cosentyx shows sustained 4 years response in ankylosing spondylitis.- Novartis.

Novartis announced new data showing Cosentyx (secukinumab) delivered sustained ASAS response rates, a measure to evaluate improvements in the signs and symptoms of ankylosing spondylitis (AS), out to four years. The data, from the phase III MEASURE 2 study, show that ASAS20 response was achieved in a high proportion (73.3%) of AS patients treated with Cosentyx 150 mg at Year 4. Data presented from 106 patients treated with Cosentyx 150 mg or those initially treated with placebo who switched to Cosentyx 150 mg for four years, showed 73.3% achieved at least a 20% improvement in AS symptoms at four years, as measured by the Assessment of Spondyloarthritis International Society response criteria (ASAS20), a standard tool used to assess clinical improvement in AS.

Additionally, more than half (60.5%) achieved an ASAS40 response at Week 208. These data add to the body of evidence for Cosentyx, the first interleukin-17A antagonist, to demonstrate efficacy in controlled Phase III AS studies. The safety profile was consistent with that observed in previous studies and similar across arms, with no new adverse events identified. The long-term four year data were presented during the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.